[ TIE-UP ]
Jubilant Enters Research
Collaboration With AstraZeneca

Jan Lundberg

Jubilant Biosys Ltd, the Bangalore-based subsidiary of Jubilant Organosys Ltd, has signed a research collaboration agreement with US major AstraZeneca, focusing on delivering novel drugs into the international pharmaceutical company’s pre-clinical pipeline.

Hari S. Bhartia

Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca. AstraZeneca will own the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant will be eligible to receive research funding spanning an initial five-year period. In addition, AstraZeneca will also pay Jubilant success- based development milestones, as well as royalties based on successful commercialization worldwide of any of the compounds, a company statement said.

Shyam S. Bhartia

Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, issued a statement on this collaboration that said: "We are very pleased to partner with AstraZeneca, this collaboration will leverage the innovative capabilities of AstraZeneca and Jubilant Biosys in providing a robust global drug discovery model. Through this partnership, Jubilant is confident of contributing to AstraZeneca’s preclinical portfolio and anticipates significant rewards from successful downstream milestones. This partnership furthers Jubilant’s strategy to be India’s largest provider of innovative and integrated pharmaceutical solutions, enabling the global pharmaceutical industry’s quest to discover affordable innovative medicines."

Jan Lundberg, executive vice president, global discovery, AstraZeneca says, "This collaboration complements our internal capabilities and increases the capacity of our pre-clinical programs. It is a concrete example of the innovative approaches we are taking to deliver a sustainable discovery pipeline with a lean and agile organization."

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: http://www.astrazeneca.com

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 300 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

The main company, Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. It has a presence across the pharmaceutical value chain for products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, nonsteriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare.

Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.

[ BY RITU PANDEY ]